The Indian firm is relocating manufacturing operations in New Jersey, from its Cranbury facility to New Brunswick, in an effort to “improve cost efficiencies” across the US.
A proposed regulation in New Jersey demonstrates a lack of understanding regarding the clinical trial process and has clear collateral damage to research conduct in the state, ACRO testifies.
The commercial compliance solutions company is expanding its footprint with a new office and anticipates further growth in the US and internationally to keep pace with client demand, says CEO.
Biopharma logistics provider Marken has opened its newest office and warehouse in Philadelphia, which is part of a global drug distribution network comprised of 10 cGMP compliant depots and more than 40 locations around the world.
CRO TKL Research is constructing a new clinical research facility that will include a 30-bed, Phase I unit as well as multiple, outpatient clinical examination rooms.
The full impact of Superstorm Sandy is still being assessed, but early reports suggest that the East coast contract manufacturing industry has escaped relatively unscathed.
US biotech Emergent BioSolutions has bought a manufacturing facility from Maryland’s MdBio Foundation is a bid to expand its production infrastructure.
US R&D facilities in Rahway and Kenilworth, New Jersey will remain operational as they are vital to the to the newly formed Merck Schering-Plough group, according to CEO Richard Clark.
The number of pharma employees in New Jersey, US fell by 1,400 in 2008, with R&D expenditure, capital investment and product trials also declining, according to a report.
To accompany the map detailing job losses, which can be viewed here, we have picked out the details and trends from the data, uncovering the state of US pharmaceutical employment in 2008.
People employed in the pharmaceutical industry in New Jersey, USA fell by one per cent in 2007, according to a report by the HealthCare Institute of New Jersey (HINJ).
Laureate Pharma is planning to invest up to $9m (€7.1m) to expand
its biopharmaceutical manufacturing facility in New Jersey with a
new pilot production plant, as it seeks more capacity to cope with
increased demand from clients for...
The trials and tribulations affecting US generics maker Able
Laboratories took a decisive turn yesterday when the company filed
for Chapter 11 bankruptcy protection, reports Phil Taylor.
